THE RECOMMENDED DOSE OF MYLOTARG IS 9 MG/M2, INFUSED OVER A 2-HOUR PERIOD.
PHYSICIANS SHOULD CONSIDER LEUKOREDUCTION WITH HYDROXYUREA OR LEUKAPHERESIS TO REDUCE THE PERIPHERAL WHITE BLOOD COUNT TO BELOW 30,000/?L PRIOR TO ADMINISTRATION OF MYLOTARG. APPROPRIATE MEASURES (E.G.
HYDRATION AND ALLOPURINOL) MUST BE TAKEN TO PREVENT HYPERURICEMIA. PATIENTS SHOULD RECEIVE THE FOLLOWING PROPHYLACTIC MEDICATIONS ONE HOUR BEFORE MYLOTARG ADMINISTRATION: DIPHENHYDRAMINE 50 MG PO AND ACETAMINOPHEN 650-1000 MG PO; THEREAFTER, TWO ADDITIONAL DOSES OF ACETAMINOPHEN 650-1000 MG PO, ONE EVERY 4 HOURS AS NEEDED. VITAL SIGNS SHOULD BE MONITORED DURING INFUSION AND FOR FOUR HOURS FOLLOWING INFUSION. THE RECOMMENDED TREATMENT COURSE WITH MYLOTARG IS A TOTAL OF 2 DOSES WITH 14 DAYS BETWEEN THE DOSES. FULL RECOVERY FROM HEMATOLOGIC TOXICITIES IS NOT A REQUIREMENT FOR ADMINISTRATION OF THE SECOND DOSE.
METHYLPREDNISOLONE GIVEN PRIOR TO MYLOTARG INFUSION MAY AMELIORATE INFUSION-RELATED SYMPTOMS.